Science Pool

Evotec presents strategic roadmap towards precision medicine and confirms goals of Action Plan 2025 at Capital Markets Day

Evotec SE today presents at its virtual Capital Markets Day how artificial intelligence (“AI”) and machine learning (“ML”) enabled precision technologies in discovery and development processes are driving up Probability of Success (“PoS”), i.e. an increasing rate of approvals in the long-run. To leverage the power of molecular data, Evotec is launching E.MPD, the Company’s molecular patient database. E.MPD is one of the largest and highest quality molecular databases globally.

Read More